Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 11/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15453076 | 0.85 | LMNA (0.59) | LMNAGAAKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL7100551 | 0.84 | LMNA (0.54) | LMNAGAAKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL15797688 | 0.83 | LMNA (0.50) | LMNAGAAKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL29615915 | 0.81 | LMNA (0.51) | LMNAGAAKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL20363566 | 0.79 | LMNA (0.50) | LMNAGAAKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL3175414 | 0.79 | LMNA (0.50) | LMNAGAAKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL17442565 | 0.79 | LMNA (0.50) | LMNAGAAKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1129788 | 0.79 | LMNA (0.63) | LMNAGAAKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1845901 | 0.78 | SMN1; SMN2 (0.55) | LMNAGAAKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL10935298 | 0.77 | LMNA (0.47) | LMNAGAAKDM4EKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370419-B1 | MALTOL ETHER PROCESSES AND INTERMEDIATES | SHIONOGI & CO (JP) | 2017-09-27 | — | — | EP | disclosed |
| CN-105646423-A | Maltol ether processes and intermediates | 盐野义制药株式会社 | 2016-06-08 | — | — | CN | disclosed |
| US-8710249-B2 | Maltol ether processes and intermediates | SHIONOGI & CO., LTD. (JP) | 2014-04-29 | — | — | US | disclosed |
| EP-2370419-A4 | MALTOL ETHER PROCESSES AND INTERMEDIATES | SHIONOGI & CO (JP) | 2012-06-27 | — | — | EP | disclosed |
| CN-102239155-A | Process and intermediates for the production of maltitol ethers | SHIONOGI & CO | 2011-11-09 | — | — | CN | disclosed |
| US-20110245516-A1 | MALTOL ETHER PROCESSES AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-2370419-A1 | MALTOL ETHER PROCESSES AND INTERMEDIATES | Shionogi&Co., Ltd. (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-2370419-A1 | MALTOL ETHER PROCESSES AND INTERMEDIATES | Shionogi&Co., Ltd. (JP) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010067176-A1 | MALTOL ETHER PROCESSES AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067176-A1 | MALTOL ETHER PROCESSES AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245516-A1 | MALTOL ETHER PROCESSES AND INTERMEDIATES | CYP3A4, CYP2E1, MALT1 | LMNA 4109/4885GAA 314/4885KDM4E 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.